All cases of combined carcinoid and non-small cell lung cancer are summarized, focusing on clinical, morphological, and biological features, suggesting the need to recognize and include this entity as a separate class, in particular for its distinct therapeutic implications.
N. Rossi, P. Parente, Luisella Righi et al.· 0 citations
OBJECTIVE
As treatment strategies evolve in advanced or metastatic endometrial cancer (EC), quality of life (QoL) has become a key parameter in evaluating therapeutic value. This systematic review summarizes QoL outcomes from pivotal trials that have shaped clinical practice in advanced EC.
METHODS
Data from phase II...
V. Tuninetti, A. Farolfi, Simona Butticè et al.· Tumori· 0 citations
Abstract Background Patients with prostate cancer (PC) frequently receive multiple medications for comorbidities, increasing the risk of drug–drug interactions (DDIs). Despite guidelines highlighting DDI relevance, data on real-world management are limited. This international survey aimed to characterize current practi...
A. A. Valsecchi, M. Maffezzoli, M. Cursano et al.· The Oncologist· 0 citations
Immune checkpoint inhibitor (ICI)–based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCT...
A. A. Valsecchi, M. Maffezzoli, M. Cursano et al.· Cancer Metastasis Review· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.